Xiaoying Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoying Xu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Boyi Li
School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
2 shared publications - Guoqiang Qian
School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China
2 shared publications - Haizhou Zeng
School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
2 shared publications - Huimei Hu
School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
2 shared publications - Qiuxiong Yin
School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
2 shared publications - Yupeng Jiang
School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
2 shared publications
Latest Publications
- Open Access
- 24 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10262
Sinisan Alleviates Stress-Induced Intestinal Dysfunction and Depressive-like Behaviors in Mice with Irritable Bowel Syndrome by Enhancing the Intestinal Barrier and Modulating Central 5-Hydroxytryptamine
Irritable bowel syndrome (IBS) is a common chronic functional bowel disorder and is strongly associated with an increased risk of depression and anxiety. The brain–gut axis plays an important role in the pathophysiologic changes in IBS, yet effective treatments for IBS are still lacking. Sinisan, originating from the Treatise on Typhoid Fever by the medical sage Zhang Zhongjing, is a classic formula in the Eight Methods of Traditional Chinese Medicine (TCM) that focuses on dispersing the liver and regulating the spleen, relieving depression and transmitting evils, and has been widely used in the treatment of liver-depression and spleen-deficiency, diarrhea, and related liver and stomach disorders. However, the therapeutic effect of sinisan in IBS has not been clarified. The aim of this study was to investigate the effects of sinisan on stress-induced intestinal dysfunction and depressive behavior in IBS mice. We established a diarrhea-predominant irritable bowel syndrome (IBS-D) mouse model using a 4% acetic acid enema combined with restraint stress, and analyzed the results using behavioral tests, relevant test kits, hematoxylin-eosin (HE) staining, immunofluorescence (IF), Western blot (WB), and quantitative fluorescence polymerase chain reaction (qRT-PCR). The results showed that sinisan administration significantly alleviated intestinal dysfunction and depressive-like behaviors in IBS-D mice, improved mild colonic inflammation and intestinal mucosal permeability, up-regulated the expression of tight junction proteins ZO-1 and occludin. Sinisan significantly alleviated intestinal dysfunction and depressive-like behaviors in IBS-D mice by decreasing the expression of TNF-α, promoting the expression of tight junction proteins (occludin, ZO-1) expression, and inhibiting the Tlr4/Myd88 signaling pathway, thereby attenuating the inflammatory response, protecting the intestinal barrier, and alleviating symptoms in the IBS-D mouse model. Taken together, sinisan may ameliorate intestinal inflammation and the intestinal barrier by regulating 5-HT expression and the Tlr4/Myd88 pathway, thereby alleviating stress-induced intestinal dysfunction and depressive behaviors in IBS-D mice.
- 24 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10262
Open AccessSinisan Alleviates Stress-Induced Intestinal Dysfunction and Depressive-like Behaviors in Mice with Irritable Bowel Syndrome by Enhancing the Intestinal Barrier and Modulating Central 5-Hydroxytryptamine
Irritable bowel syndrome (IBS) is a common chronic functional bowel disorder and is strongly associated with an increased risk of depression and anxiety. The brain–gut axis plays an important role in the pathophysiologic changes in IBS, yet effective treatments for IBS are still lacking. Sinisan, originating from the Treatise on Typhoid Fever by the medical sage Zhang Zhongjing, is a classic formula in the Eight Methods of Traditional Chinese Medicine (TCM) that focuses on dispersing the liver and regulating the spleen, relieving depression and transmitting evils, and has been widely used in the treatment of liver-depression and spleen-deficiency, diarrhea, and related liver and stomach disorders. However, the therapeutic effect of sinisan in IBS has not been clarified. The aim of this study was to investigate the effects of sinisan on stress-induced intestinal dysfunction and depressive behavior in IBS mice. We established a diarrhea-predominant irritable bowel syndrome (IBS-D) mouse model using a 4% acetic acid enema combined with restraint stress, and analyzed the results using behavioral tests, relevant test kits, hematoxylin-eosin (HE) staining, immunofluorescence (IF), Western blot (WB), and quantitative fluorescence polymerase chain reaction (qRT-PCR). The results showed that sinisan administration significantly alleviated intestinal dysfunction and depressive-like behaviors in IBS-D mice, improved mild colonic inflammation and intestinal mucosal permeability, up-regulated the expression of tight junction proteins ZO-1 and occludin. Sinisan significantly alleviated intestinal dysfunction and depressive-like behaviors in IBS-D mice by decreasing the expression of TNF-α, promoting the expression of tight junction proteins (occludin, ZO-1) expression, and inhibiting the Tlr4/Myd88 signaling pathway, thereby attenuating the inflammatory response, protecting the intestinal barrier, and alleviating symptoms in the IBS-D mouse model. Taken together, sinisan may ameliorate intestinal inflammation and the intestinal barrier by regulating 5-HT expression and the Tlr4/Myd88 pathway, thereby alleviating stress-induced intestinal dysfunction and depressive behaviors in IBS-D mice.
- Open Access
- 23 October 2023
- Published by Springer Nature in Research Square
Saikosaponin B1/D alleviate dextran sulfate sodium- induced colitis via regulating the NRF2/HO-1 pathway to inhibit the ferroptosis in zebrafish
Background: Inflammatory bowel disease (IBD) is a chronic and recurrent gastrointestinal inflammation, the pathophysiological mechanisms of that is not fully understood, and the current conventional treatment drugs are often associated with serious side effects. Saikosaponins(SSs) are the main active component of Bupleurum chinense DC. (BC). Saikosaponin A has been reported to have a positive effect on the remission of DSS induced colitis. Aim: However, the studies on the mechanism and safety of SSs are still limited. Materials and methods: We established zebrafish colitis model induced by sodium glucan sulfate (DSS) and gave intervention treatment with different saikosaponins. Results : It was found that saikosaponin B1 (SSB1) and saikosaponin D (SSD) had the most prominent inhibitory ability on neutrophils infiltration in the larval intestine among the 6 saikosaponin monomers. In this study, we explored the effect and mechanism of SSB1 and SSD on DSS induced colitis in zebrafish. The results showed that both SSB1 and SSD could reduce the histological injury, tissue inflammatory cytokines and ROS expression in zebrafish. Moreover, we observed that both SSB1 and SSD significantly inhibited ferroptosis in DSS stimulated zebrafish colitis. In Conclusion: conclusion, our results suggested that Saikosaponin B1/D play a protective role in inhibiting ferroptosis by up-regulating NRF2/HO-1 pathway.
- 23 October 2023
- Published by Springer Nature in Research Square
Open AccessSaikosaponin B1/D alleviate dextran sulfate sodium- induced colitis via regulating the NRF2/HO-1 pathway to inhibit the ferroptosis in zebrafish
Background: Inflammatory bowel disease (IBD) is a chronic and recurrent gastrointestinal inflammation, the pathophysiological mechanisms of that is not fully understood, and the current conventional treatment drugs are often associated with serious side effects. Saikosaponins(SSs) are the main active component of Bupleurum chinense DC. (BC). Saikosaponin A has been reported to have a positive effect on the remission of DSS induced colitis. Aim: However, the studies on the mechanism and safety of SSs are still limited. Materials and methods: We established zebrafish colitis model induced by sodium glucan sulfate (DSS) and gave intervention treatment with different saikosaponins. Results : It was found that saikosaponin B1 (SSB1) and saikosaponin D (SSD) had the most prominent inhibitory ability on neutrophils infiltration in the larval intestine among the 6 saikosaponin monomers. In this study, we explored the effect and mechanism of SSB1 and SSD on DSS induced colitis in zebrafish. The results showed that both SSB1 and SSD could reduce the histological injury, tissue inflammatory cytokines and ROS expression in zebrafish. Moreover, we observed that both SSB1 and SSD significantly inhibited ferroptosis in DSS stimulated zebrafish colitis. In Conclusion: conclusion, our results suggested that Saikosaponin B1/D play a protective role in inhibiting ferroptosis by up-regulating NRF2/HO-1 pathway.